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Pharmacological correction of obesity-induced
autophagy arrest using calcium channel blockers
Hwan-Woo Park1, Haeli Park1, Ian A. Semple1, Insook Jang1, Seung-Hyun Ro1, Myungjin Kim1, Victor A. Cazares1,
Edward L. Stuenkel1, Jung-Jae Kim2, Jeong Sig Kim1,3 & Jun Hee Lee1
Autophagy deregulation during obesity contributes to the pathogenesis of diverse metabolic
disorders. However, without understanding the molecular mechanism of obesity interference
in autophagy, development of therapeutic strategies for correcting such defects in obese
individuals is challenging. Here we show that a chronic increase of the cytosolic calcium
concentration in hepatocytes during obesity and lipotoxicity attenuates autophagic flux by
preventing the fusion between autophagosomes and lysosomes. As a pharmacological
approach to restore cytosolic calcium homeostasis in vivo, we administered the clinically
approved calcium channel blocker verapamil to obese mice. Such treatment successfully
increases autophagosome–lysosome fusion in liver, preventing accumulation of protein
inclusions and lipid droplets and suppressing inflammation and insulin resistance. As calcium
channel blockers have been safely used in clinics for the treatment of hypertension for more
than 30 years, our results suggest they may be a safe therapeutic option for restoring
autophagic flux and treating metabolic pathologies in obese patients.
DOI: 10.1038/ncomms5834
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M
acroautophagy (hereafter referred to as autophagy) is a
highly conserved bulk degradation system that is
responsible for degrading long-lived cytoplasmic
proteins, protein aggregates, lipid droplets and damaged or
excess organelles. An isolation membrane or phagophore expands
and encloses a portion of cytosol to form a double-membrane
vesicular structure called autophagosome. An autophagosome
then fuses with a lysosome to degrade its sequestered contents by
lysosomal enzymes1,2. Autophagy has been shown to be
important for regulating physiological functions such as protein
turnover, lipid droplet digestion and organelle quality control3,4.
Defects in autophagy are found in various pathological conditions
including cancer, obesity, steatosis, insulin resistance and
neurodegenerative diseases5–7.
Lipotoxicity occurs when excessive free fatty acids become
accumulated in non-adipose tissues or cells such as hepatocytes
and pancreatic cells, contributing to pathogenesis of obesity,
diabetes and their related metabolic disorders8–10. Saturated fatty
acids (SFA) are known to cause more lipotoxic effects that can
lead to steatosis and cell apoptosis than unsaturated fatty acids
(UFA)11,12. SFA can cause endoplasmic reticulum (ER) stress and
c-Jun N-terminal kinases (JNK) activation as well by increasing
ER membrane rigidity12,13. The reduction in ER membrane
fluidity results in inhibition of sarco-ER calcium pump (SERCA),
which subsequently elevates cytosolic calcium level. Thapsigargin
(Tg), a pharmacological agent known to inhibit SERCA, can
provoke autophagosome accumulation by specifically inhibiting
autophagy at the autophagosome–lysosome fusion step14,15.
Obesity and SFA also induce autophagosome accumulation;
however, it has been elusive whether this is due to increased
autophagosome formation or decreased autophagosome
degradation16–22.
p62, also known as sequestosome-1, is a scaffold protein that
plays multiple roles in signalling pathways23. In autophagy, p62 is
important for targeting ubiquitinated proteins to be transported
to the autophagic machinery for their clearance in lysosomes23.
However, association of ubiquitinated proteins with p62 is not
sufficient for autophagic removal, and for this reason,
p62-associated ubiquitinated protein aggregates are often
identified in diseased tissues of liver dysfunction, neuro-
degeneration and cancer24. Because genetic deletion of p62
actually alleviates the detrimental consequences of autophagy
defects in many pathological contexts25–27, accumulation of p62
has been considered harmful rather than beneficial for cells.
Notably, obesity induces excessive accumulation of p62 and
ubiquitinated proteins inside liver, which is an early marker of
non-alcoholic steatohepatitis (NASH) pathologies24,28,29.
These findings collectively indicate that obesity causes defective
autophagy20,22,29. To examine how lipotoxicity, thus obesity,
affects autophagy, we developed an in vitro system where cultured
human hepatoma (HepG2) cells exhibit prominent accumulation
of p62 and ubiquitinated proteins in insoluble inclusion bodies on
SFA treatment. As protein inclusion formation was revealed to be
a consequence of arrested autophagic flux, we were interested in
finding appropriate pharmacological methods that could reverse
the effect of SFA on autophagy and protein homeostasis. We
found in this study that calcium channel blockers, which can
decrease cytosolic calcium level in SFA-treated cells, can restore
the autophagic flux and prevent metabolic pathologies associated
with autophagy defects. Our results also show that a chronic
increase in cytosolic calcium concentration and subsequent
inhibition of autophagosome–lysosome fusion are the causes of
autophagy arrest during SFA treatment and obesity. Therefore,
our study provides an explanation on how obesity-associated
lipotoxicity interferes with autophagy overall and suggests a new
therapeutic strategy for the obesity-associated autophagy defects.
Results
SFA induces p62- and ubiquitin-positive inclusions. During
obesity and NASH, excessive fat accumulation inside hepatocytes
can provoke formation of protein inclusions consisting of p62
and ubiquitinated proteins24,28. Since the process of inclusion
body formation was yet to be explored, we devised an in vitro
system that made it possible to examine the effect of lipids on
protein aggregation. We found that, in response to palmitic acid
(PA, 500mM), which is a long-chain SFA that becomes highly
elevated in sera of obese individuals, human HepG2 hepatoma
cells formed a considerable amount of insoluble cytoplasmic
inclusions consisting of ubiquitinated proteins and p62
(Fig. 1a–c). PA-induced accumulation of protein inclusions had
a proportional correlation with both dose (Supplementary Fig. 1)
and time (Supplementary Fig. 2a); correspondingly, when treated
for a longer period (48 h), even a very low dose of PA (50 mM)
was able to induce substantial protein inclusions (Supplementary
Fig. 1b). Although prolonged treatment of high-dose PA (24 and
48 h, 500 mM) provoked apoptosis, there was no significant cell
death at 9 h of PA treatment (Supplementary Fig. 3), a time point
at which we observed the greatest amount of prominent protein
inclusions (Fig. 1a–c; Supplementary Fig. 2a). The inclusions were
frequently associated with condensed fibres of keratin
(Supplementary Fig. 4a) or tubulin (Supplementary Fig. 4b) as
observed previously for various protein aggregates28,30. It is
interesting to note that the protein aggregates were located away
from the ER structure (Supplementary Fig. 4c) in which many
unfolded proteins typically accumulate during lipotoxicity and
obesity13. Although another SFA stearic acid (SA) was also able to
induce accumulation of p62 (Supplementary Fig. 2b), UFA such
as oleic acid (OA) and docosahexaenoic acid (DHA) failed to
induce such accumulation (Supplementary Fig. 2c,d) and actually
suppressed the effect of SFA (Supplementary Fig. 2e,f).
SFA induces accumulation of autophagosomes. Because
defective autophagy can explain excessive accumulation of p62
and ubiquitinated proteins31, we examined the level of
autophagosomes in cells with an autophagosome marker LC3
(ref. 32). During autophagosome formation, LC3 precursor
(LC3-I) is proteolytically cleaved and lipidated for
incorporation into an autophagosomal membrane as LC3-II.
SFA, but not UFA, induced prominent accumulation of
autophagosomes as manifested by increased LC3-II levels
(Supplementary Fig. 2a–f). The patterns of LC3-II expression
directly correlated with the patterns of p62 levels (Supplementary
Fig. 2a–f), and LC3-positive autophagosomes were frequently
co-localized with p62 inclusions in SFA-treated cells (Fig. 1d).
SFA inhibits fusion between autophagosomes and lysosomes.
To determine whether SFA induces autophagosome accumula-
tion through increased formation or decreased degradation of
autophagosomes, we examined autophagy flux in SFA-treated
cells through three independent assays32. For all assays, cells
treated with an autophagy inducer rapamycin were used as a
positive control. In the first assay, we incubated cells with
bafilomycin, which halts autophagosome degradation by
disrupting lysosomal pH homeostasis, and examined the
amount of newly formed autophagosomes through LC3-II
immunoblotting. As expected, control cells (both untreated and
rapamycin-treated cells) showed significantly increased LC3-II
levels after bafilomycin application (Supplementary Fig. 2g,h). In
contrast, PA-treated cells did not exhibit any increase in LC3-II
level following bafilomycin addition (Supplementary Fig. 2g,h),
suggesting that decreased degradation, rather than increased
formation, is the cause of PA-induced autophagosome
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accumulation. The second assay involved staining PA-treated
cells with anti-LC3-II and anti-LAMP1 antibodies to visualize
autophagosomes and lysosomes, respectively. Although there was
a considerable level of association between autophagosomes and
lysosomes in control cells, such association was hardly observed
in PA-treated cells (Fig. 1e,f). We finally utilized an autophagy
flux indicator mCherry-GFP-LC3 in the third assay. mCherry-
GFP-LC3 initially fluoresces both red and green as it labels
autophagosomes. On fusion with lysosomes that exposes
mCherry-GFP fluorophore to acidic environment, GFP is
denatured and loses its green colour while mCherry maintains
its red fluorescence. Thus, all autolysosomes fluoresce only red
once the fusion is complete. Although control cells exhibited both
autophagosomes and autolysosomes, autolysosomes were very
scarce in PA-treated cells (Fig. 1g,h). These results collectively
indicate that SFA inhibits autophagic flux mainly by blocking the
fusion between autophagosomes and lysosomes.
Stress pathways do not mediate autophagy arrest on SFA. We
then tried to determine how SFA can cause a defect in autophagic
flux and induce protein inclusion. Several potential physiological
consequences of SFA treatment include ceramide accumulation33,
oxidative stress34, ER stress35 and JNK signalling activation12.
However, these are signals known to stimulate, rather than
inhibit, the autophagic flux in various systems36–38, suggesting
that these stress pathways may be irrelevant to the effect of SFA
on autophagy. To test this, we inhibited ceramide biosynthesis by
L-cycloserine and fumonisin B1 (Supplementary Fig. 5a),
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Figure 1 | SFA induces protein inclusions and arrests autophagy. (a–f) HepG2 cells were treated with bovine serum albumin (Con), 500mM PA or
100nM rapamycin (Rap) for 9 h and subjected to following analyses. (a,c–f) Cells were stained with ubiquitin (Ub), p62, LC3 and LAMP1 antibodies and
DAPI (blue). Boxed areas are magnified in right-most panels (c,d). Co-localization between LAMP1 and LC3 staining (e) was quantified (f; n¼ 3). (b) Cells
were subjected to serial protein extraction (solubility fractionation) with indicated concentration of Triton X-100 (TX100) or sodium dodecyl sulphate
(SDS) and analysed by immunoblotting with indicated antibodies. (g,h) HepG2 cells stably transduced with mCherry (mCh)-GFP-LC3-expressing
retroviruses were treated with Con, Rap or PA for 9 h and examined under a live confocal microscope (g). Yellow dots represent autophagosomes while red
dots indicate autolysosomes in which GFP signal was faded out. Number of autolysosomes was quantified (h; n¼ 7). Scale bar, 5 mm. All data are shown
as mean±s.e.m. ***Po0.001 (Student’s t-test). Molecular weight markers are indicated in kDa.
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suppressed oxidative stress by butylated hydroxyanisole (BHA)
and N-acetylcysteine (NAC; Supplementary Fig. 5b), reduced ER
stress by a chemical chaperone tauroursodeoxycholic acid
(TUDCA; Supplementary Fig. 5c) and inhibited JNK by
SP600125 (Supplementary Fig. 5d). We also inhibited three ER
stress sensor molecules, pancreatic ER kinase (PERK;
Supplementary Fig. 5e), inositol-requiring enzyme 1 alpha
(IRE1a; Supplementary Fig. 5f) and activating transcription
factor 6 (ATF6; Supplementary Fig. 5g) through lentiviruses
expressing small hairpin RNA (shRNA) or dominant-negative
mutants targeting these molecules. As expected, none of these
interventions significantly suppressed the accumulation of p62
and autophagosomes by SFA (Supplementary Fig. 5), suggesting
that these signals do not mediate SFA-induced autophagy arrest.
SFA induces protein inclusions by inhibiting SERCA. We
became aware of several recent reports that Tg, an inhibitor of
SERCA and inducer of ER stress, could inhibit fusion between
autophagosomes and lysosomes14,15. Because SFA is also known
to inhibit SERCA by decreasing ER membrane fluidity13, we
postulated that SERCA inhibition may provide a common basis
for the autophagic arrest induced by Tg and SFA. Confirming the
aforementioned reports14,15, Tg, as well as other SERCA
inhibitors such as 2,5-t-butylhydroquinone (TBHQ) and
cyclopiazonic acid (CPA), inhibited the association between
autophagosomes and lysosomes (Supplementary Fig. 6a), arrested
autophagic flux (Supplementary Fig. 6b,c) and induced
accumulation of p62 and LC3-II (Supplementary Fig. 6d–f), in
the same way as SFA (Fig. 1; Supplementary Fig. 2). However,
tunicamycin (Tm), an ER stress inducer unrelated to SERCA,
did not interfere with autophagic flux (Supplementary Fig. 6b,c)
and actually decreased p62 levels (Supplementary Fig. 6d,e,g),
supporting the idea that SERCA inhibition, rather than ER stress
induction, is the cause of SFA- and Tg-induced autophagy arrest
and protein inclusion formation. shRNA-mediated silencing of
SERCA2 also provoked p62 accumulation (Supplementary
Fig. 6h), while overexpression of SERCA2, which can overcome
the obesity-mediated SERCA inhibition39,40, was able to prevent
SFA-induced formation of p62/ubiquitinated protein aggregates
(Supplementary Fig. 6i,j). These data all strongly indicate that
SFA-dependent inhibition of SERCA is the cause of autophagy
inhibition and the resulting protein inclusion formation.
SFA does not alter lysosomal calcium or proton levels. Because
both endogenous and overexpressed SERCA proteins were absent
from lysosomal or autophagosomal membranes (Supplementary
Fig. 7a,b), it is not likely that SERCA controls luminal calcium
homeostasis in either organelle. Luminal calcium or proton levels
of lysosomes, which are important for the autophagosome–
lysosome fusion process41, were indeed unaffected by SERCA
inhibition after SFA or Tg treatment (Supplementary Fig. 7c,d).
SFA arrests autophagy through elevating cytosolic calcium.
SFA-mediated elevation in cytosolic calcium level due to pro-
longed SERCA inhibition (Fig. 2a–d)13 may be the cause of the
SFA-induced autophagy defect. This increase in calcium level was
substantially averted by application of verapamil and nicardipine,
two structurally unrelated calcium channel blockers that prevent
leakage of extracellular calcium into cytoplasm (Fig. 2a–d). To
our surprise, application of verapamil and nicardipine strongly
reduced SFA-induced accumulation of p62 and ubiquitinated
proteins in the insoluble compartments of cells (Fig. 2e–h).
Immunofluorescence microscopy confirmed that the calcium
channel blockers very effectively prevented SFA-induced
formation of p62 and ubiquitinated protein inclusions
(Fig. 2i,j). The calcium channel blockers also restored the
association between autophagosomes and lysosomes in SFA-
treated cells (Fig. 2k,l). Taken together, these results indicate that
chronic elevation of cytosolic calcium level, which can be averted
by calcium channel blockers, is primarily responsible for
SFA-induced autophagy arrest and protein inclusion formation.
Calcium channels are expressed in liver cells. Many voltage-
dependent calcium channels, the targets of verapamil and
nicardipine, are expressed in both HepG2 cells and mouse liver
(Supplementary Fig. 8a–e)42. shRNA-mediated silencing of
a1D/Cav1.3, the most highly expressed calcium channel isoform
in HepG2 cells (Supplementary Fig. 8d)42, significantly decreased
p62 protein inclusion in SFA-treated cells (Supplementary
Fig. 8e,f), although the decrease in ubiquitinated protein
inclusion was not as apparent. The incompleteness in
restoration suggests that a1C/Cav1.2 or other unknown calcium
channels may have contributed to the hepatocyte calcium influx
during SFA treatment.
Prolonged calcium influx induces protein inclusions. Glucagon,
phenylephrine and vasopressin, which can elevate cytosolic cal-
cium level in hepatocytes through activation of inositol trispho-
sphate receptor43, were able to induce protein inclusions
(Supplementary Fig. 9a), although the extent of this induction
was substantially less than those due to high-dose SFA (500 mM).
In contrast, ryanodine receptor agonists, which can elevate
cytosolic calcium concentration in muscles and neurons, had
minimal effects on protein inclusions (Supplementary Fig. 9b)
most likely because ryanodine receptors are not expressed in liver
cells44,45, or even if expressed, they play a relatively minor role46.
Verapamil suppresses hepatosteatosis. Because of the dramatic
effect calcium channel blockers had in restoring autophagy flux
in vitro (Fig. 2), we proceeded to use a mouse model of obesity to
determine whether they could be a viable therapeutic option for
obesity-associated autophagy defects and associated pathologies.
Ten days of verapamil administration slightly reduced body
weight of high-fat diet (HFD)-kept obese mice (Fig. 3a) without
any substantial change in food consumption rates (Fig. 3b).
Although livers from control mice under HFD displayed pink
colour due to fat accumulation (hepatosteatosis), the colour of
livers from verapamil-administered mice was normal red
(Fig. 3c). The liver mass was also significantly reduced by
verapamil administration (Fig. 3d), while the weight of epididy-
mal white adipose tissue remained the same (Fig. 3e). Although
verapamil exerted minimal effects on the expression of adipokines
and adipocytokines in epididymal white adipose tissue
(Fig. 3f–h), hematoxylin and eosin staining and Oil Red O
staining confirmed that verapamil reduced HFD-induced
accumulation of hepatic lipid droplets (Fig. 3i,j).
Verapamil reduces obesity-induced cytosolic calcium in liver.
We confirmed that verapamil modulated calcium homeostasis
in mouse hepatocytes; HFD-induced autophosphorylation of
calcium/calmodulin-dependent protein kinase II (CaMKII)47,48,
which is indicative of an elevated level of cytosolic calcium
in hepatocytes49, was strongly suppressed by verapamil
administration (Fig. 3k,l). PA-induced elevation of cytosolic
calcium level in primary mouse hepatocytes was also suppressed
by verapamil (Fig. 3m).
Verapamil restores autophagic flux in liver of obese mice. We
examined the level of protein inclusion formation in obese mouse
liver. As formerly reported29,50, obesity induced prominent
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accumulation of p62 and ubiquitinated proteins in insoluble
fractions of liver lysates (Fig. 4a–d). The protein inclusions,
however, almost completely disappeared after administration of
verapamil (Fig. 4a–d), demonstrating that verapamil is capable of
resolving HFD-induced accumulation of both lipid droplets and
protein inclusions. Immunohistochemistry of p62 in mouse liver
also confirmed that verapamil administration is sufficient to
eliminate p62-containing protein inclusions induced by obesity
(Fig. 4e,f). As observed in SFA-treated HepG2 cells, HFD induced
accumulation of insoluble LC3-II (Fig. 5a,b), most likely as a
result of fusion defects between autophagosomes and lysosomes.
Indeed, obesity substantially decreased the association between
autophagosomes and lysosomes in mouse liver (Fig. 5c,d) in
consistence with previous reports6,22. Verapamil administration
allowed autophagosomes and lysosomes to re-associate (Fig. 5c,d)
and subsequently suppressed accumulation of LC3-II in obese
mouse liver (Fig. 5a,b). Thus, as observed in cultured cells,
calcium channel blockers can restore the fusion between
autophagosomes and lysosomes and subsequently autophagic
removal of protein inclusions and lipid droplets in vivo.
Verapamil suppresses ER stress in liver of obese mice. Because
autophagy is important for suppressing ER stress29, we examined
whether verapamil-mediated resumption of autophagy could
suppress ER stress in liver of obese mice. Phosphorylation of
eukaryotic translation initiation factor 2-alpha (eIF2a) and
induction of binding immunoglobulin protein expression,
which are ER stress signalling markers elevated in mouse liver
on HFD-induced obesity51, were both strongly suppressed by
verapamil administration (Supplementary Fig. 10a–c).
Verapamil suppresses steatohepatitis. Liver inflammation,
characterized by increased macrophage infiltration into the liver,
is a hallmark of NASH pathologies in addition to accumulation of
lipid droplets and protein inclusions52. Because liver inflam-
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mation can be provoked by either HFD-induced obesity53 or
genetic inhibition of autophagy26,54, we were interested in the
effect that calcium channel blockers may have on resolving
obesity-associated liver inflammation. Verapamil administration
was found to reduce liver inflammation in livers from HFD-kept
obese mice, as manifested by decreased macrophage number that
is comparable to that of low-fat diet-kept lean mice (Fig. 6a,b).
These results add more evidence that calcium channel blockers
can have a potential as therapeutics for NASH pathologies.
Verapamil suppresses obesity-induced insulin resistance. In
addition to being responsible for accumulation of lipid droplets
and protein inclusions6,26,31, autophagy defects and NASH can
both promote the development of insulin resistance29,52, the
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quantitative reverse transcription–PCR. (i,j) Liver sections were analysed by hematoxylin and eosin (H&E, upper panels) and Oil Red O (ORO, lower panels)
staining (i). ORO densities were quantified (j). (k,l) Calcium-induced CaMKII autophosphorylation in livers was analysed by immunoblotting (k) and
quantified (l). (m) Primary hepatocytes from 2-month-old C57BL/6 mice kept on LFD were treated with bovine serum albumin (Con), PA (500mM),
PAþverapamil (Ver, 50mM) or PAþ nicardipine (Nic, 100mM) for 12 h. After each treatment, cells were loaded with a calcium indicator Fura-2-AM.
Calcium levels were visualized by dual fluorescent microscopy at 340/380nm, and ratio of fluorescence intensities of Fura-2-AM at 340 nm over 380nm
was quantified (n¼ 17). Scale bar, 1 cm (c), 200mm (i). All data are shown as mean±s.e.m. *Po0.05, **Po0.01, ***Po0.001 (Student’s t-test). Molecular
weight markers are indicated in kDa.
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infamous precursor of type 2 diabetes. Thus, we questioned
whether calcium channel blockers could be used for correcting
insulin resistance in HFD-kept obese mice. HFD-induced obesity
provoked glucose intolerance (Fig. 6c,d) and insulin resistance
(Fig. 6e,f) in mice as formerly reported55. Intriguingly, verapamil
administration strongly suppressed both metabolic pathologies;
glucose intolerance (Fig. 6c,d) and insulin resistance (Fig. 6e,f)
were restored back to the normal level by verapamil
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mean±s.e.m. *Po0.05, **Po0.01, ***Po0.001 (Student’s t-test). Molecular weight markers are indicated in kDa.
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administration. Serum insulin level (Fig. 6g) and pancreatic islet
size (Fig. 6h,i) were significantly decreased by verapamil
administration, indicating that obesity-associated hyper-
insulinemia56 was also suppressed. These results suggest that
calcium channel blockers can be effective for correction of insulin
resistance and blood glucose homeostasis defects during obesity.
Verapamil improves cardiac functionality in obese mice.
Finally, we tested the effect of verapamil on blood pressure and
cardiac functionality, which are partially controlled by voltage-
dependent calcium channels. Verapamil administration induced
only a slight decrease in blood pressure of HFD-kept obese mice,
which was not enough to reach the level of statistical significance
(Fig. 7a). We also did not observe substantial changes in heart
size; left ventricular (LV) wall mass (Fig. 7b) and diastolic LV
volume (Fig. 7c) remained similar between verapamil-treated and
-untreated groups. Intriguingly, there was a significant reduction
in systolic LV volume (Fig. 7d) and an increase in LV ejection
fraction (% EF; Fig. 7e), suggesting that heart contractility
may have been improved by verapamil treatment. However,
verapamil-induced elevation of LV stroke volume and cardiac
output was not statistically significant (Fig. 7f,g).
Discussion
The autophagy signalling pathway has been extensively studied in
the context of hypernutrition and obesity in recent years, and
there is now a general consensus that autophagy deregulation
contributes to the pathogenesis of diverse obesity-associated
metabolic disorders7,20,22,29,57–60. However, as the molecular
mechanism of obesity interference in autophagy has been
obscure, we have not yet been able to develop effective
therapeutic strategies for correcting autophagy defects in obese
individuals. Our current report suggests that lipotoxicity-induced
elevation of cytosolic calcium is primarily responsible for the
autophagy defects observed during obesity. Chronic increase in
cytosolic calcium level specifically inhibits the fusion between
autophagosomes and lysosomes, thereby attenuating the
autophagic flux. This attenuation leads to prominent
accumulation of undegraded autophagy substrates such as
ubiquitinated proteins, p62 aggregates and lipid droplets,
ultimately resulting in excessive fat accumulation, ER stress,
liver inflammation and insulin resistance. As calcium channel
blockers can prevent the cytosolic calcium influx, they have high
potential as therapeutic candidates for correcting obesity-induced
autophagy defects and preventing their pathological
consequences. Indeed, both non-dihydropyridine (verapamil)
and dihydropyridine (nicardipine) calcium channel blockers
were effective in restoring the autophagic flux and suppressing
protein inclusion formation during lipotoxicity.
Various calcium channel blockers have been on the pharma-
ceutical market for around 30 years, and there have been many
clinical/pre-clinical studies on their effect on metabolism. To
identify specific papers on this subject, we have utilized a
computerized natural language processing/text mining tool to
screen all the abstracts published in the MEDLINE database61.
Using this method, we were able to identify 39 papers that
describe the causal relationship between calcium channel blockers
and metabolic homeostasis in humans or animals. Among them,
25 papers, including several very recent ones62,63, indicate that
calcium channel blockers can improve glucose metabolism and/or
liver homeostasis (Supplementary Table 1a), which is consistent
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Figure 6 | Verapamil reduces liver inflammation and improves metabolic homeostasis. Four-month-old C57BL/6 male mice kept on HFD for 2 months
were subjected to daily administration of phosphate-buffered saline (Con, n¼4) or verapamil (Ver, 25mg per kg body weight, i.p., n¼ 3) for 10 days.
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with our current findings. Many of these papers examine animals
or humans associated with either obesity or type 2 diabetes, and
these subjects are likely to have obesity/lipotoxicity-associated
autophagy defects, which are correctable by calcium channel
blockers.
In contrast, 14 papers were identified to indicate neutral or
even negative effects of calcium channel blockers on metabolism
(Supplementary Table 1b). Specifically, one large meta-analysis of
long-term clinical trials demonstrates that calcium channel
blockers are not effective in preventing incidental diabetes in
hypertensive patients64. However, we should take into account
that, even though autophagy is important for prevention of
metabolic pathologies and diabetes29, autophagic defects, which
are correctable by calcium channel blockers, may not be the only
cause for diabetes. Thus, it is feasible that calcium channel
blocker-mediated restoration of the autophagic flux could not
prevent the occurrence of incidental diabetes in certain cases, as
they may have arisen from causes other than autophagy
misregulation. Nevertheless, our study does suggest that
calcium channel blockers have a clinical potential for a subset
of patients with NASH and type 2 diabetes whose symptoms are
indeed associated with lipotoxicity-induced autophagy arrest. It
would therefore be worthwhile to conduct more rigorous human
clinical studies focused on the possible usage of calcium channel
blockers for NASH and other obesity-associated metabolic
pathologies.
Methods
Antibodies and reagents. Ubiquitin (sc-8017), LAMP1 (sc-20011), phospho-
PERK (sc-32577), PERK (sc-13073), phospho-c-Jun (sc-822), c-Jun (sc-376488),
SERCA2 (sc-376235, sc-8095), ATF6 (sc-22799), eIF2a (sc-11386), CaMKII
(sc-5306), a1C/Cav1.2 (sc-16229-R), a1D/Cav1.3 (sc-25687), LC3 (sc-271625) and
p62 (sc-28359) antibodies were obtained from Santa Cruz Biotechnology. IRE1a
(3294), phospho-CaMKII (12716), phospho-eIF2a (3398), PERK (5683), LC3
(2775), p62 (5114) and calnexin (2679) antibodies were purchased from Cell
Signaling Technology. Pan-keratin antibody was obtained from Dr Omary
(University of Michigan (UM))65. Actin (JLA20) and tubulin (T5168) antibodies
were purchased from Developmental Studies Hybridoma Bank and Sigma,
respectively. Fatty acid-free and low-endotoxin bovine serum albumin, PA, SA,
OA, DHA, Tm, Tg, BHA, NAC, chlorocresol, L-cycloserine, glucagon,
phenylephrine, vasopressin, verapamil and nicardipine were purchased from
Sigma. SP600125, bafilomycin and rapamycin were from LC Labs, and fumonisin
B1 and suramin were from Cayman Chemical.
Cell culture. HepG2 cells (gift from Dr Saltiel), a human hepatoma cell line, were
cultured in DMEM (Invitrogen) containing 10% fetal bovine serum (Sigma),
50Uml 1 penicillin and 50mgml 1 streptomycin. All cultures were maintained
in a 37 C incubator with 5% CO2. De-lipidated low-endotoxin bovine serum
albumin was loaded with different fatty acids and applied to cultured cells12.
Viral procedures. The lentiviral plasmid for sh-SERCA2 (Broad Institute TRC
Portal accession code TRCN0000038532), sh-PERK (TRCN0000001401 and
TRCN0000001399), sh-ATF6 (TRCN0000017853) and sh-a1D (TRCN0000044693
and TRCN0000044695) was purchased from Open Biosystems (Huntsville, AL).
Lentiviral LAMP1-mRFP, Lentiviral IRE1aDN and retroviral mCherry-GFP-LC3
constructs were obtained from Addgene (Cambridge, MA). Adenoviruses
expressing the 2b isoform of SERCA (Ad-SERCA2b) were gifts from
Dr Hotamisligil40. Viruses were generated and amplified in the Vector Core
facility at the UM.
Solubility fractionation. Cells were lysed in a lysis buffer66 containing 0.1% Triton
X-100. Cell and tissue lysates were centrifuged at 15,000 r.p.m. for 15min at 4 C to
separate pellets from supernatants. Pellets were resuspended in a lysis buffer
containing 1% Triton X-100 and then subjected to centrifugation at 15,000 r.p.m.
for 15min at 4 C. After centrifugation, pellets were resuspended in a lysis buffer
containing 2% SDS and boiled in SDS sample buffer. Liver tissues were directly
lysed in a lysis buffer containing 1% Triton X-100 and centrifuged at 15,000 r.p.m.
for 15min at 4 C. Pellets were dissolved in a lysis buffer containing 2% SDS.
Supernatants (soluble fraction) and resuspended pellets (insoluble fraction) were
boiled in SDS sample buffer.
Immunoblotting. Unless otherwise noted, cells and tissues were lysed in radio-
immunoprecipitation assay buffer (50mM Tris–HCl, pH 7.4; 150mM NaCl; 1%
deoxycholate Na; 1% NP-40; 0.1% SDS; and complete protease inhibitor cocktail
(Roche)). Lysates were centrifuged at 15,000 r.p.m. for 15min at 4 C. Lipid layer
was removed and supernatant was collected. Protein concentration was measured
using Bio-rad protein assay kit. Lysates were boiled in SDS sample buffer for 5min,
separated by SDS–polyacrylamide gel electrophoresis, transferred to polyvinylidene
fluoride membranes and probed with primary antibodies (1:200 for Santa Cruz
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Figure 7 | Effects of verapamil on blood pressure and cardiac functionality of obese mice. (a–g) Four-month-old C57BL/6 male mice kept on HFD
for 2 months were subjected to daily administration of phosphate-buffered saline (Con, n¼4) or verapamil (Ver, 25mg per kg body weight, i.p., n¼4)
for 10 days. Systolic blood pressure (a), LV wall mass (b), diastolic LV volume (c), systolic LV volume (d), ejection fraction (e, % EF), stroke volume
(f, SV) and cardiac output (g, CO) were analysed by tail-cuff method (a) or echocardiography (b–g). All data are shown as mean±s.e.m. *Po0.05
(Student’s t-test).
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antibodies, and 1:1,000 for Cell Signaling and Developmental Studies Hybridoma
Bank antibodies). After incubation with secondary antibodies conjugated with
horseradish peroxidase (1:2,000), chemiluminescence was detected using LAS4000
(GE) systems. Uncropped images of immunoblots presented in the main paper are
provided in Supplementary Information (Supplementary Fig. 11).
Immunocytochemistry and TUNEL analysis. Cells grown on coverslips were
fixed with 4% paraformaldehyde and incubated overnight with primary antibodies
(1:50 for Santa Cruz antibodies, 1:200 for pan-keratin and tubulin antibodies and
1:400 for Cell Signaling antibodies). After washing, cells were incubated with Alexa
Fluor-conjugated secondary antibodies (Invitrogen, 1:250) for 1.5 h and counter-
stained with 40,6-diamidino-2-phenylindole (DAPI; Invitrogen). Apoptotic cells
were determined by TUNEL (terminal dUTP nick-end labeling) with In Situ Cell
Death Detection Kit-TMR-Red (Roche). Samples were analysed under an
epifluorescence-equipped microscope (Meiji) or a laser confocal microscope
(Olympus).
RNA analysis. Total RNA was extracted from tissues or cells using Trizol reagent
(Invitrogen), and complementary DNA was made using MMLV-RT (Invitrogen)
and random hexamers (Invitrogen). Quantitative reverse transcription–PCR was
performed in a Real-Time PCR detection system (Applied Biosystems) with iQ
SYBR Green Supermix (Bio-rad) and relevant primers (Supplementary Table 2).
Relative mRNA expression was calculated from the comparative threshold cycle
(Ct) values relative to mouse b-actin or human cyclophilin A. To determine human
XBP1 splicing, PCR products of spliced (XBP1-s) and unspliced (XBP1-u) XBP1
mRNA were separated by electrophoresis on a 2.5% agarose gel and visualized by
ethidium bromide staining.
Calcium measurements. For lysosomal calcium measurements, we performed
Oregon Green 488 BAPTA-1 dextran (OGBD) labelling41. In this assay, cells with a
stable transduction of LAMP1-mRFP lentiviruses were loaded with 0.1mgml 1
OGBD (Invitrogen) for 30min. For cytosolic calcium measurements, we performed
X-Rhod-1 and Fura-2 labelling assays. In these assays, cells were loaded with 1 mM
X-Rhod-1-AM (Invitrogen) or 1 mM Fura-2-AM (Invitrogen) for 30min. For
OGBD and X-Rhod-1 imaging, the cells were examined under a temperature- and
CO2-controlled laser confocal microscope (Olympus); for ratiometric Fura-2
imaging, cells were examined under a temperature- and CO2-controlled
fluorescence microscope equipped with excitation wavelengths of 340 and 380 nm
(Till Polychrome V, Till Photonics, Gra¨felfing, Germany), a 410-dLcp beamsplitter,
a D510/80 wide-band emission filter (Chroma Technology, Rockingham, VT,
USA) and a Quant-EM camera (Photometrics, Tucson, AZ, USA).
LysoSensor staining. For LysoSensor labelling, cells with stable transduction of
LAMP1-mRFP lentiviruses were stained with 1 mM LysoSensor Green DND-189
(Invitrogen) for 30min. After washing with phosphate-buffered saline, live cells
were imaged immediately on a temperature- and CO2-controlled laser confocal
microscope (Olympus).
Mice and diets. Mice were maintained in filter-topped cages and were given free
access to autoclaved regular chow diet (low-fat diet) or HFD (S3282, Bio-Serv) and
water at the UM according to the NIH and institutional guidelines. The strain,
sex and age of mice for each experiment are described in the corresponding figure
legend section. All animal studies were ethically approved (protocol approval
number: PRO00001461) and overseen by the University Committee on Use and
Care of Animals at the UM.
Glucose and insulin tolerance tests. For glucose and insulin tolerance tests, mice
were starved for 6 h. Blood was drawn from a tail nick at the indicated time points
after i.p. injection of glucose (1 g per kg body weight) or insulin (0.65U per kg body
weight). Blood glucose was instantly measured with OneTouch Ultra glucose meter
(Lifescan). Serum insulin levels were measured with an ultrasensitive mouse insulin
ELISA kit (Crystal Chem). Mice were tested for insulin resistance at 5 days and
glucose tolerance at 7 days after initiation of phosphate-buffered saline and
verapamil treatments.
Histology. Tissues were fixed in 10% formalin or embedded in Tissue-Tek opti-
mum cutting temperature (OCT) compound (Sakura Finetek) for paraffin or
frozen block preparation, respectively. Paraffin-embedded tissues were used for
hematoxylin and eosin or immunohistochemical staining of p62 (1:50) and F4/80
(1:100). Frozen tissue sections were stained with Oil Red O or immunostained with
LC3 (1:400) and LAMP1 (1:50) antibodies. Hematoxylin or DAPI counterstaining
was applied to visualize nuclei. Samples were analysed under a light microscope
(Meiji) or a laser confocal microscope (Olympus).
Primary cell culture. Primary mouse hepatocytes were isolated and cultured
from livers of 2-month-old lean mice by a two-step collagenase digestion with
100Uml 1 collagenase in Hank’s Balanced Salt Solution at pH 7.4. After
dissection, the liver was placed in DMEM and carefully pulled apart to release
hepatocytes. Hepatocytes in DMEM were passed through a 100-mm cell strainer
and then spun at 50g for 1min. The pellet was resuspended in DMEM and then
spun at 50g for 10min in a Percoll gradient to remove dead hepatocytes. The viable
primary hepatocytes were washed with DMEM at 50g for 10min and cultured in
10% fetal bovine serum and DMEM.
Echocardiography. Induction of anaesthesia was performed in an enclosed
container filled with 5% isoflurane. After induction, the mice were placed on a
warming pad to maintain body temperature. Isoflurane (1–1.5%) was supplied via a
nose cone to maintain a surgical plane of anaesthesia. Hair was removed from the
upper abdominal and thoracic area with depilatory cream. Transthoracic echo-
cardiography was performed in the supine or left lateral position. Two-dimensional
(2D) and M-mode echocardiographic images were recorded using a Vevo 2100
high-resolution in vivo micro-imaging system (Visual Sonics). We measured LV
ejection fraction from the 2D long axis view. In addition, we measured systolic and
diastolic dimensions and wall thickness by M-mode in the parasternal short axis
view at the level of the papillary muscles. Fractional shortening and ejection
fraction were also calculated from the M-mode parasternal short axis view.
Noninvasive blood pressure measurement. Systolic blood pressure was mea-
sured using a BP-2000 noninvasive tail-cuff system (Visitech, Apex, NC)67.
Quantification and statistics. Immunoblot images were quantified by densito-
metry, and protein expressions were expressed as relative band intensities.
Fluorescence images were analysed using ImageJ (NIH) software equipped with
Just Another Co-localization Plugin (JACoP). Relative calcium levels were
quantified from cells by the cytosolic intensity of X-Rhod-1 fluorescence or by the
ratio between Fura-2 intensities at 340 nm and 380 nm. Co-localization of different
proteins was expressed as Pearson’s coefficient. Statistical significance of differences
between two groups was calculated using a Student’s t-test. P values equal to or
above 0.05 were considered not statistically significant (NS).
Literature search. In addition to the keyword-based literature search, semantic-
based text mining was conducted utilizing the previously described algorithm61.
One hundred and seventy-one texts that imply causal relationships between
‘Amlodipine, Aranidipine, Azelnidipine, Barnidipine, Benidipine, Cilnidipine,
Clevidipine, Isradipine, Efonidipine, Felodipine, Lacidipine, Lercanidipine,
Manidipine, Nicardipine, Nifedipine, Nilvadipine, Nimodipine, Nisoldipine,
Nitrendipine, Pranidipine, Verapamil, Gallopamil, Fendiline, Diltiazem,
Mibefradil, Bepridil, Flunarizine, Fluspirilene, Fendiline’ and ‘Glucose, Fat, Lipid,
Free fatty acid, Insulin, Hyperglycemia, Diabetes, Hepatosteatosis, Steatohepatitis,
Inflammation, Autophagy, Glucose intolerance, Insulin resistance’ were discovered
from the MEDLINE abstract database. These pre-screened texts were manually
examined to identify papers that describe the metabolic effect of calcium channel
blockers in human and animal systems.
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